The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry

J Gynecol Oncol. 2015 Jan;26(1):19-24. doi: 10.3802/jgo.2015.26.1.19. Epub 2014 Oct 13.

Abstract

Objective: In this study we utilized the Surveillance, Epidemiology and End-Results (SEER) registry to identify risk factors for lymphatic spread and determine the incidence of pelvic and para-aortic lymph node metastases in patients with uterine papillary serous carcinoma (UPSC) and uterine clear cell carcinoma (UCCC) who underwent complete surgical staging and lymph node dissection.

Methods: Nine hundred seventy-two eligible patients diagnosed between 1998 to 2009 with International Federation of Gynecology and Obstetrics (FIGO) 1988 stage IA-IVA UPSC (n=685) or UCCC (n=287) were identified for analysis. Binomial logistic regression was used to determine risk factors for lymph node metastasis, with the incidence of pelvic and para-aortic lymph node metastases reported for each FIGO primary tumor stage. The Cox proportional hazards regression model was used to determine factors associated with overall survival.

Results: FIGO primary tumor stage was the only independent risk factor for lymph node metastasis (p<0.01). The incidence of pelvis-only and para-aortic lymph node involvement according to the FIGO primary tumor stage were as follows: IA (2.3%/3.8%), IB (7.5%/5.2%), IC (22.5%/16.9%), IIA (20.8%/13.2%), IIB (25.7%/14.9%), and III/IV (25.7%/24.3%). Prognostic factors for overall survival included lymph node involvement (hazard ratio [HR], 1.42; 95% confidence interval [CI], 1.09 to 1.85; p<0.01), patient age >60 years (HR, 1.70; 95% CI, 1.21 to 2.41; p<0.01), and advanced FIGO primary tumor stage (p<0.01). Tumor grade, histologic subtype, and patient race did not predict for either lymph node metastasis or overall survival.

Conclusion: There is a high incidence of both pelvic and para-aortic lymph node metastases for FIGO stages IC and above uterine papillary serous and clear cell carcinomas, suggesting a potential role for lymph node-directed therapy for these patients.

Keywords: Adenocarcinoma Clear Cell; Lymphatic Metastasis; Pelvis; Registries; Risk Factors.

MeSH terms

  • Adenocarcinoma, Clear Cell / epidemiology
  • Adenocarcinoma, Clear Cell / pathology
  • Adenocarcinoma, Clear Cell / secondary*
  • Adenocarcinoma, Clear Cell / surgery
  • Adult
  • Aged
  • Aged, 80 and over
  • Aorta, Abdominal
  • Cystadenocarcinoma, Papillary / epidemiology
  • Cystadenocarcinoma, Papillary / pathology
  • Cystadenocarcinoma, Papillary / secondary*
  • Cystadenocarcinoma, Papillary / surgery
  • Cystadenocarcinoma, Serous / epidemiology
  • Cystadenocarcinoma, Serous / pathology
  • Cystadenocarcinoma, Serous / secondary*
  • Cystadenocarcinoma, Serous / surgery
  • Female
  • Humans
  • Incidence
  • Kaplan-Meier Estimate
  • Lymph Node Excision
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Pelvis
  • SEER Program
  • United States / epidemiology
  • Uterine Neoplasms / epidemiology*
  • Uterine Neoplasms / pathology
  • Uterine Neoplasms / surgery